| Literature DB >> 35306625 |
Rachel Gur-Arie1, Nadav Davidovitch2, Anat Rosenthal2.
Abstract
We propose an emerging conceptualization of "intervention hesitancy" to address a broad spectrum of hesitancy to disease prevention interventions among healthcare personnel (HCP) beyond vaccine hesitancy. To demonstrate this concept and its analytical benefits, we used a qualitative case-study methodology, identifying a "spectrum" of disease prevention interventions based on (1) the intervention's effectiveness, (2) how the intervention is regulated among HCP in the Israeli healthcare system, and (3) uptake among HCP in the Israeli healthcare system. Our cases ultimately contribute to a more nuanced conceptualization of hesitancy that HCP express towards disease prevention interventions. Our case interventions included the seasonal influenza vaccine, the Mantoux test, and the hepatitis B (HBV) vaccine. Influenza and HBV are vaccine-preventable diseases, though their respective vaccines vary significantly in effectiveness and uptake among HCP. The Mantoux test is a tuberculin skin test which provides a prevention benchmark for tuberculosis (TB), a non-vaccine preventable disease. We conducted semi-structured interviews with relevant stakeholders and analyzed them within Israeli and international policy context between 2016 and 2019, a period just prior to the COVID-19 pandemic. We propose the conceptualization of "intervention hesitancy"-beyond "vaccine hesitancy"-as "hesitancy towards a wide range of public health interventions, including but not limited to vaccines". Results suggested that intervention hesitancy among HCP is rooted in weak trust in their employer, poor employment conditions, as well as mixed institutional guidelines and culture. Conceptualizing intervention hesitancy expands the ability of healthcare systems to understand the root of hesitancy and foster a supportive institutional culture and trust, cognizant of diverse disease prevention interventions beyond vaccination.Entities:
Keywords: Healthcare personnel; Infection control; Intervention hesitancy; Nonpharmaceutical interventions; Occupational health; Policy; Trust; Vaccines
Year: 2022 PMID: 35306625 PMCID: PMC8934537 DOI: 10.1007/s40592-022-00152-w
Source DB: PubMed Journal: Monash Bioeth Rev ISSN: 1321-2753
Interviewee Demographics, HCP and Stakeholders
| Interviewee | Title | Gender | Training (when available) |
|---|---|---|---|
| 1 | District Epidemiological Nurse, Ministry of Health | Female | Nurse |
| 2 | Former Director of Israeli Center for Disease Control, Ministry of Health Professor | Female | MD (Family and Community Medicine), PhD |
| 3 | District Physician Chairman, Advisory Committee on Infectious Diseases and Immunizations, Ministry of Health Professor | Male | MD (Family and Community Medicine), MPH |
| 4 | Department Head, Public Health, Sick Fund Headquarters | Female | Nurse |
| 5 | District Public Health Nurse, Ministry of Health | Female | Nurse, PhD |
| 6 | Director, National Center for Infection Control, Ministry of Health Professor | Male | MD (Internal Medicine and Infectious Disease) |
| 7 | Former Head, Public Health and Occupational Health, Ministry of Health Professor | Female | MD, MPH (Family and Community Medicine) |
| 8 | District Physician, Ministry of Health | Female | MD, MPH, MBA |
| 9 | District Physician, Ministry of Health Senior Lecturer | Male | MD, MPH |
| 10 | Head, Infectious Diseases, Sick Fund Research Institute Professor | Male | MD (Internal Medicine), MPH |
| 11 | Head District Epidemiological Nurse, Ministry of Health | Female | Nurse |
| 12 | District Epidemiological Nurse, Ministry of Health | Female | Nurse |
| 13 | Head, Public Health Physician Association Professor | Male | MD (Family and Community Medicine), MPH |
| 14 | Head, Department of Pediatrics and Pediatric Infectious Diseases, Major Hospital | Male | MD (Pediatrics and Infectious Disease) |
| 15 | Head, Tuberculosis and AIDS, Ministry of Health Professor | Male | MD |
| 16 | Head Nurse, Occupational Health, Sick Fund Clinic | Female | Nurse |
| 17 | Global Epidemiologist Professor Emeritus | Male | MD (Infectious Disease) |
| 18 | Founding Director, Health and Risk Communication Center Professor | Female | PhD |
| 19 | Head, Infection Surveillance and Medical Data Monitoring, National Center for Infection Control, Ministry of Health | Male | MD (Internal Medicine), MPH |
| 20 | Director of Occupational Health, Sick Fund Headquarters | Male | MD (Environmental and Occupational Health) |
Overview of Diseases and Associated Case Disease Prevention Interventions
| Influenza | Tuberculosis (TB) | Hepatitis B (HBV) | |
|---|---|---|---|
|
| Acute respiratory infection caused by influenza virus (strains A, B, C) ((WHO) 2018) Airborne ((WHO) 2018) Seasonal ((WHO) 2018) | Caused by bacteria Mycobacterium tuberculosis (WHO Affects lungs primarily (WHO Top 10 global death causes (WHO Treatable with antimicrobials (WHO Airborne (WHO | Virus attacks the liver and causes hepatic dysfunction (Baghianimoghadam et al. Acute and chronic disease 33% of world population infected (350 mil chronic, 65% asymptomatic) (Baghianimoghadam et al. Percutaneous/mucosal exposure to blood/bodily fluids (Ziglam et al. |
|
| Increased occupational risk (Kuster et al. 1 of 5 of HCP: symptomatic for influenza annually (Kuster et al. | Increased occupational risk (Napoli et al. Risk for MDR-TB (multi drug resistant TB) 6x higher among HCP than among patients (Napoli et al. Dutch study: 42% of HCP with TB infected at work (de Vries et al. | Increased occupational risk (Ziglam et al. Contracted through needle sticks, sharp device exposure, infected non-skin contact, splash injuries (Ziglam et al. Pre-vaccination era: 5-10% of HCP became chronic carriers (Roggendorf and Viazov |
|
| Seasonal Influenza Vaccine 1 annual dose (Pearson | Mantoux/Tuberculin Test upon hire/annually (Chemtob | HBV Vaccine 3 doses over 6 month period (Burnett et al. |
|
| Inconclusive CDC: 2017–2018 seasonal vaccine 25% effective (against H3N2) but reduced medically-attended influenza by 59% among children (Flannery et al. | Hypersensitivity test which is a global standard (Sosa et al. | HCP show substantial immunity after even just 1 dose (Zuckerman et al. 88% developed sero-protection (Averhoff et al. Over 18 year period: 98.8% persistence of anti-HBs (Averhoff et al. |